Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices

References

• Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16(1):19–30. doi:10.1007/s12519-019-00229-3
   PubMed Web of Science ®Google Scholar
• Larosa M, Zen M, Gatto M, et al. IL-12 and IL-23/Th17 axis in SLE. Exp Biol Med. 2019;244:42–51. doi:10.1177/1535370218824547
   PubMed Web of Science ®Google Scholar
• Fischer K, Przepiera-Będzak H, Sawicki M, Walecka A, Brzosko I, Brzosko M. Serum interleukin-23 in Polish patients with systemic lupus erythematosus: association with lupus nephritis, obesity, and peripheral vascular disease. Hindawi Mediators Inflamm. 2017;2017:9. doi:10.1155/2017/9401432
   Web of Science ®Google Scholar
• Comte D, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. Lupus. 2015;24:351–363. doi:10.1177/0961203314556139
   PubMed Web of Science ®Google Scholar
• Yanti T, Yuliasih RLD. IL-23/IL-17 axis and disease activity in systemic lupus erythematosus patients. Eurasia J Biosci. 2020;14:2643–2649.
   Google Scholar
• Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202::96–105. doi:10.1111/j.0105-2896.2004.00214.x
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221–242. doi:10.1146/annurev.immunol.22.012703.104758
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R b1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–5708. doi:10.4049/jimmunol.168.11.5699
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–240. doi:10.1084/jem.20041257
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412. doi:10.1002/art.40930
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–640. doi:10.1002/art.1780350606
   PubMed Web of Science ®Google Scholar
• Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–369. doi:10.1002/art.1780390303
   PubMed Web of Science ®Google Scholar
• Aringer M. Inflammatory markers in systemic lupus erythematosus. J Autoimmun. 2020;110:102374. doi:10.1016/j.jaut.2019.102374
   PubMed Web of Science ®Google Scholar
• Yap DYH, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol. 2010;2010:365083. doi:10.1155/2010/365083
   PubMedGoogle Scholar
• Moreno-Torres V, Castejón R, Martínez-Urbistondo M, et al. Serum cytokines to predict systemic lupus erythematosus clinical and serological activity. Clin Transl Sci. 2022;15:1676–1686. doi:10.1111/cts.13283
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517. doi:10.1146/annurev.immunol.021908.132710
   PubMed Web of Science ®Google Scholar
• Vukelic M, Laloo A, Kyttaris VC. Interleukin 23 is elevated in the serum of patients with SLE. Lupus. 2020;29(14):1943–1947. doi:10.1177/0961203320952841
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol. 2009;183:3160–3169. doi:10.4049/jimmunol.0900385
   PubMed Web of Science ®Google Scholar
• Pan HF, Ye DQ, Li XP. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008;4:352–353. doi:10.1038/ncprheum0815
   PubMedGoogle Scholar
• Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600. doi:10.1038/nri3707
   PubMed Web of Science ®Google Scholar
• Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76(2):280–287. doi:10.1016/j.cyto.2015.05.007
   PubMed Web of Science ®Google Scholar
• Amarilyo G, Lourenco EV, Shi FD, La Cava A. IL-17 promotes murine lupus. J Immunol. 2014;193(2):540–543. doi:10.4049/jimmunol.1400931
   PubMed Web of Science ®Google Scholar
• Vaillant AJ, Akpaka PE. Cytokines (IL-17, IL-23 and IL-33) in systemic lupus erythematosus in Trinidad and Tobago. medRxiv. 2020. doi:10.1101/2020.09.27.20202762
   Google Scholar
• Yago T, Nanke Y, Kawamoto M, Kobashigawa T, Yamanaka H, Kotake S. IL-23 and Th17 disease in inflammatory arthritis. J Clin Med. 2017;6(9):81. doi:10.3390/jcm6090081
   PubMed Web of Science ®Google Scholar
• Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16:7. doi:10.1186/s12865-015-0070-7
   PubMed Web of Science ®Google Scholar
• Dedong H, Feiyan Z, Jie S, Xiaowei L, Shaoyang W. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients. Immunol Lett. 2019;210:33–39. doi:10.1016/j.imlet.2019.04.002
   PubMed Web of Science ®Google Scholar
• Kang HK, Ecklund D, Liu M, Datta SK. Apigenin. a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res Ther. 2009;11:1–13. doi:10.1186/ar2682
   Web of Science ®Google Scholar
• van Vollenhoven R, Hahn BH, Tsokos GC, et al. Maintenance of efficacy and safety and reduction of BILAG flares with ustekinumab, an interleukin-12/23 inhibitor, in patients with active systemic lupus erythematosus (SLE): 2-year results of a Phase 2, randomized placebo controlled, crossover study. Poster presented at: American College of Rheumatology (ACR); November 5–9, 2020; E-congress.
   Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–1339. doi:10.1016/S0140-6736(18)32167-6
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: 1-year results of a phase 2, randomized placebo-controlled, crossover study. Poster presented at: American College of Rheumatology (ACR) Annual Meeting; October 19–24, 2018; Chicago, IL.
   Google Scholar
• van Vollenhoven R, Hahn BH, Tsokos GC, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase 2 multicenter, prospective, randomized, double blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761–768. doi:10.1002/art.41179
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2 open-label extension study. [published online ahead of print December 01 2021]. J Rheumatol. 2021;49:380–387. doi:10.3899/jrheum.210805
   PubMed Web of Science ®Google Scholar
• Costa R, Antunes P, Salvador P, et al. Secukinumab on refractory lupus nephritis. Cureus. 2021;13(8):e17198. doi:10.7759/cureus.17198
   PubMed Web of Science ®Google Scholar
• Farah Izati A, Wong KK, Che Maraina CH. IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis. Malays J Pathol. 2020;42(3):333–347.
   PubMed Web of Science ®Google Scholar
• Santacruz J, Pulido S, Arzuaga A, Juliana Mantilla M, Santos A, Londono J. Current evidence for IL-17/23 blockade for the treatment of lupus nephritis. Cureus. 2021;13(12):e20087. doi:10.7759/cureus.20087
   PubMed Web of Science ®Google Scholar